This is an old revision of this page, as edited by 589q(talk | contribs) at 18:31, 10 January 2022(added the ISSN of the corresponding reference). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 18:31, 10 January 2022 by 589q(talk | contribs)(added the ISSN of the corresponding reference)
CUMYL-CBMICA (SGT-280) is an indole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug,[1][2] first being identified in Germany in August 2019. Since the structure fell outside the German drug analogue law provisions at the time, an amendment was made to the law to expand the relevant definition, which came into effect in April 2020.[3] It has been shown to act as a CB1 receptor agonist with an EC50 of 62.9nM.[4]
^Polettini AE, Kutzler J, Sauer C, Bleicher S, Schultis W (September 2020). "LC-QToFMS Presumptive Identification of Synthetic Cannabinoids without Reference Chromatographic Retention/Mass Spectral Information. I. Reversed-Phase Retention Time QSPR Prediction as an Aid to Identification of New/Unknown Compounds". Journal of Analytical Toxicology. 45 (5): 429–439. doi:10.1093/jat/bkaa126. ISSN0146-4760. PMID32896861.
^Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (November 2020). "in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID33253529.
